A Multicenter, randomised, Double Blind Placebo Controlled Trial Evaluating Atorvastatin in Factorial With Omega-3 Fatty Acids Cardiovascular Risk Reduction in Patients With Type 2 Diabetes.
Latest Information Update: 22 Feb 2021
At a glance
- Drugs Atorvastatin (Primary) ; Omega-3-acid ethyl esters
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms AFORRD
- Sponsors Pfizer
- 15 Nov 2006 Status change
- 15 Nov 2006 The expected completion date for this trial is now 1 Jul 2006.
- 22 Sep 2006 Status change